Lutwin Weitner

420 total citations
11 papers, 165 citations indexed

About

Lutwin Weitner is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Lutwin Weitner has authored 11 papers receiving a total of 165 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Infectious Diseases, 5 papers in Virology and 5 papers in Emergency Medicine. Recurrent topics in Lutwin Weitner's work include HIV/AIDS drug development and treatment (10 papers), HIV Research and Treatment (5 papers) and HIV-related health complications and treatments (5 papers). Lutwin Weitner is often cited by papers focused on HIV/AIDS drug development and treatment (10 papers), HIV Research and Treatment (5 papers) and HIV-related health complications and treatments (5 papers). Lutwin Weitner collaborates with scholars based in Germany, Italy and Austria. Lutwin Weitner's co-authors include Jürgen K. Rockstroh, B. Matz, Rolf Kaiser, Martin Däumer, Oliver Schildgen, Martin Vogel, Esther Voigt, Stefan Christensen, A Moll and Guenther Schmutz and has published in prestigious journals such as Clinical Infectious Diseases, AIDS and Journal of Infection.

In The Last Decade

Lutwin Weitner

10 papers receiving 159 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lutwin Weitner Germany 7 113 106 85 40 28 11 165
Kate El Bouzidi United Kingdom 8 39 0.3× 59 0.6× 98 1.2× 89 2.2× 27 1.0× 15 157
E. Wilkins United Kingdom 5 59 0.5× 76 0.7× 111 1.3× 71 1.8× 54 1.9× 7 190
Manuela Pogliaghi Italy 7 36 0.3× 48 0.5× 37 0.4× 52 1.3× 16 0.6× 11 113
Tânia Reuter Brazil 7 35 0.3× 58 0.5× 41 0.5× 10 0.3× 18 0.6× 19 94
Stephanie Popping Netherlands 6 39 0.3× 76 0.7× 64 0.8× 9 0.2× 11 0.4× 12 111
Arlette Emième Ivory Coast 6 40 0.4× 63 0.6× 57 0.7× 29 0.7× 5 0.2× 9 93
Anja Hüfner Germany 8 21 0.2× 51 0.5× 68 0.8× 80 2.0× 17 0.6× 10 137
Jean Luc Meynard France 5 25 0.2× 37 0.3× 60 0.7× 42 1.1× 24 0.9× 7 101
J. Koffi France 4 74 0.7× 73 0.7× 56 0.7× 19 0.5× 3 0.1× 6 98
Samir Dervisevic United Kingdom 7 84 0.7× 95 0.9× 117 1.4× 11 0.3× 3 0.1× 11 194

Countries citing papers authored by Lutwin Weitner

Since Specialization
Citations

This map shows the geographic impact of Lutwin Weitner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lutwin Weitner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lutwin Weitner more than expected).

Fields of papers citing papers by Lutwin Weitner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lutwin Weitner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lutwin Weitner. The network helps show where Lutwin Weitner may publish in the future.

Co-authorship network of co-authors of Lutwin Weitner

This figure shows the co-authorship network connecting the top 25 collaborators of Lutwin Weitner. A scholar is included among the top collaborators of Lutwin Weitner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lutwin Weitner. Lutwin Weitner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Ingiliz, Patrick, Lutwin Weitner, A Moll, et al.. (2011). Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV): The "Real-life Setting" proves the concept. European journal of medical research. 16(5). 237–237. 13 indexed citations
2.
Reiberger, Thomas, Martin Obermeier, B.A. Payer, et al.. (2011). Considerable Under-Treatment of Chronic HCV Infection in HIV Patients despite Acceptable Sustained Virological Response Rates in a Real-Life Setting. Antiviral Therapy. 16(6). 815–824. 27 indexed citations
3.
Lazzarin, Adriano, et al.. (2010). 5‐year safety and efficacy of the once‐daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF). Journal of the International AIDS Society. 13(S4). 4 indexed citations
4.
Weitner, Lutwin, et al.. (2009). Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT). European journal of medical research. 14(5). 195–195. 3 indexed citations
5.
Maserati, Renato, et al.. (2006). Reply to Manfredi. Clinical Infectious Diseases. 42(9). 1347–1348.
6.
Maserati, Renato, et al.. (2005). Improved Lipid Profiles and Maintenance of Virologic Control in Heavily Pretreated HIV-Infected Patients Who Switched from Stavudine to Tenofovir Treatment. Clinical Infectious Diseases. 42(1). 145–147. 12 indexed citations
7.
Voigt, Esther, Christian Schulz, Gerd Klausen, et al.. (2005). Pegylated interferon α-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. Journal of Infection. 53(1). 36–42. 30 indexed citations
8.
Schildgen, Oliver, Martin Vogel, Martin Däumer, et al.. (2004). Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. AIDS. 18(17). 2325–2327. 47 indexed citations
9.
10.
Knechten, Heribert, et al.. (2002). Treatment of HIV-associated wasting with recombinant human growth hormone: monitoring of body composition changes by bioelectrical impedance analysis (BIA).. PubMed. 7(3). 103–8. 6 indexed citations
11.
Zöllner, Bernhard, et al.. (2001). Application of HIV-1 genotypic-resistance testing prevents the evolution of further resistance mutations in heavily pretreated patients. Journal of Clinical Virology. 21(1). 37–45. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kate El Bouzidi Breakdown of academic impact, for papers by E. Wilkins Breakdown of academic impact, for papers by Manuela Pogliaghi Breakdown of academic impact, for papers by Tânia Reuter Breakdown of academic impact, for papers by Stephanie Popping Breakdown of academic impact, for papers by Arlette Emième Breakdown of academic impact, for papers by Anja Hüfner Breakdown of academic impact, for papers by Jean Luc Meynard Breakdown of academic impact, for papers by J. Koffi Breakdown of academic impact, for papers by Samir Dervisevic
Rankless by CCL
2026